.png){kind=icon}
Return
Improving Immunotherapy Through Glycodesign
.png){kind=icon}
OA
AI
DOI：10.3389/fimmu.2018.02485.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Immunotherapy is revolutionizing health care, with the majority of high impact drugs approved in the past decade falling into this category of therapy. Despite considerable success, glycosylation-a key design parameter that ensures safety, optimizes biological response, and influences the pharmacokinetic properties of an immunotherapeutic-has slowed the development of this class of drugs in the past and remains challenging at present. This article describes how optimizing glycosylation through a variety of glycoengineering strategies provides enticing opportunities to not only avoid past pitfalls, but also to substantially improve immunotherapies including antibodies and recombinant proteins, and cell-based therapies. We cover design principles important for early stage pre-clinical development and also discuss how various glycoengineering strategies can augment the biomanufacturing process to ensure the overall effectiveness of immunotherapeutics.
Keywords:
immunotherapy
glycosylation
antibody-drug conjugates (ADCs)
monoclonal antibodies
antibodydependent cell cytotoxicity (ADCC)
glycoengineering
metabolic glycoengineering
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
5.9
Papers:
5.0W
Citations:
22.7W
Organization
Cited Papers
ShareSaveAberrant Hedgehog Ligands Induce Progressive Pancreatic Fibrosis by Paracrine Activation of Myofibroblasts and Ductular Cells in Transgenic Zebrafish.png)
PLoS ONEOAAI
PLoS ONEIF0
OAAIShareSaveShareSaveShareSaveShareSave
View more